Juliette Lambert

Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

Juliette Lambert, Cécile Pautas, Christine Terré et al. · Haematologica · 2018 · 336 citations · Full text

Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity

C. Charbonnel, R. Convers-Domart, Sophie Rigaudeau et al. · European Heart Journal - Cardiovascular Imaging · 2016 · 106 citations

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia

Élise Fournier, Nicolas Duployez, Benoît Ducourneau et al. · Blood · 2019 · 82 citations · Full text

MRD assessed by<i>WT1</i>and<i>NPM1</i>transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

Juliette Lambert, Jérôme Lambert, Olivier Nibourel et al. · Oncotarget · 2014 · 80 citations · Full text

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Claude Gardin, Cécile Pautas, Élise Fournier et al. · Blood Advances · 2020 · 80 citations · Full text